The present invention relates to a method of forming a nanocrystal which includes cadmium.
Inorganic nanoparticles find a wide range of applications including e.g. as coloring agents (e.g. in stained glass windows), catalysts, as magnetic drug delivery, hypothermic cancer therapy, contrast agents in magnetic resonance imaging, magnetic and fluorescent tags in biology, solar photovoltaics, nano bar codes or emission control in diesel vehicles.
Semiconductor nanoparticles, typically nanocrystals, that confine the motion of conduction band electrons, valence band holes, or excitons (in all three spatial directions) can serve as “droplets” of electric charge and are termed quantum dots. Quantum dots can be as small as 2 to 10 nanometers, with self-assembled quantum dots typically ranging between 10 and 50 nanometers in size.
Quantum dots have attracted interest for various uses, including electronics, fluorescence imaging and optical coding. They are of particular importance for optical applications due to their theoretically high quantum yield. In electronic applications they have been proven to operate like a single-electron transistor and show the Coulomb blockade effect.
Solid state lighting devices such as light-emitting diodes (LEDs) have become an application for quantum dots. The efficiency of LEDs very much depends on the quality of their emitting layers, which traditionally, are inorganic layers prepared via physical evaporation or molecular beam epitaxy approach. The merit of these LEDs is the photostability, providing long life-time for the devices; the drawbacks were expensive facilities, critical fabrication conditions, and low efficiency. The use of organic and polymeric dye as the emitting layer increased the efficiency and makes the fabrication easier; however, the low stability of these dyes at elevated temperature or in presence of light shortened the life-time of the device dramatically. Colloidal quantum dots with high Quantum Yield and of easy-processible character provided the possibility of producing LEDs with both the merits of inorganic and organic LEDs prepared previously, i.e., using quantum dots embedded polymer matrices (aka, polymer/quantum dots nanocomposite, polymer/quantum dots hybrid materials, etc) as emitting layers (Achermann, M., et al., Nature [2004] 429, 642-646).
One of the most successful routes to prepare high-quality semiconductor quantum dots is the decomposition of molecular precursors at high temperatures in a coordinating solvent (for an overview of previous techniques see e.g. Reed, M. A., Scientific American (1993), January, 118-123), possibly, in the presence of a negative ion source, e.g., TOP/Se, TOP/S, etc. This process was developed in 1993 by Murray et al. (J. Am. Chem. Soc. (1993), 115, 8706-8715) and yields quantum dots of CdE (E=Se, S, and Te). It involves the formation of a solution of dimethylcadmium in tri-n-octylphosphine (TOP) and a solution of the corresponding chalcogenide in TOP. The solutions are combined and rapidly injected into tri-n-octylphosphine oxide (TOPO) at high temperatures (200° C.-300° C.). Thereby TOP/TOPO capped nanocrystals are obtained. The capping agent allows particle solubility in organic solvents, and plays a crucial role in preventing particle aggregation and electronically passivating the semiconductor surface. A similar approach has been also used for the preparation of ZnS and ZnSe nanoparticles, CdSe/ZnS, CdSe/CdS, and CdSe/ZnSe with core/shell nanostructures. CdSe nano crystals have become the most extensively investigated quantum dots because of their ease of preparation and size-tuneable photoluminescence across the visible spectrum.
This so-called TOPO method permits the production of highly monodisperse nanoparticles in quantities of hundreds of milligrams in one single experiment. However a great hindrance for its development on a large scale is represented by the high temperatures employed and by the toxicity of the starting materials.
Most of the illumination used in daily life resembles sunlight, i.e., white-emission. This explains the demand in developing white-emitting materials. White-emitting polymer/quantum dots hybrid materials have also been demonstrated. The most widely applied strategy was to mix quantum dots with different size thus providing the emission of different colours into a polymer matrix to achieve an overall white light emission, following the R-G-B principle (i.e., mixture of red-green-blue light leads to white light). Such a strategy, however, may be limited due to some potential problems: 1) possibility of the inhomogeneous distribution of the quantum dots with different colours within the matrix, leading to domination or deficiency of one single colour in certain sections; 2) difficulties in controlling inter-particle distances, resulting in fluorescence resonance energy transfers (FRET) in which the light emitted with short-wavelength is absorbed by larger size particle. Deficiency of the short wavelength emitting light leads to failure of the white light formation. Reducing the concentration of the quantum dots in polymer matrix might reduce the FRET possibility, but does not necessarily help white-light emission; 3) device performance failure if three types of quantum dots show different photo- or thermal stabilities. All these limit the application of quantum dots to a large extent.
A solution for the above-mentioned problems appeared in 2005 (Bowers, M. J., J. Am. Chem. Soc. [2005] 127, 15378-15379). In this report quantum dots with ‘magic size’ were prepared in a modification of the TOPO method. Into a solution of cadmium oxide and dodecylphosphonic acid in a mixture of TOPO and hexadecylamine a solution of selenium in TOP and octadecene was injected at high temperatures (330° C.). Due to the rich surface states these quantum dots emitted light with long wavelengths besides their intrinsic emission in the blue light range. The overall emitted light was a pure white light. Though white emitting quantum dots can be prepared following this approach, the required critical reaction conditions and operation make it impossible for scale-up productions. A new approach for producing similar quantum dots at mild conditions with easy operation is necessary.
Another problem preventing quantum dots (even the coloured ones) from wide use is the high cost, which is a consequence of the difficulties in preparation (high temperature, harsh treatment, etc), purification (exhaustive washes with high consumption of solvents and effort), and the scale-up problems. Therefore there exists a need for new approaches helpful for lowering the production cost of quantum dots.
It is therefore an object of the present invention to provide a method that provides at least essentially monodisperse nanoparticles of a cadmium chalcogenide that overcomes at least some of the above explained difficulties.
In one aspect the present invention provides a method of forming a nanocrystal of the composition CdA, with A being S or Se. The method includes forming in a suitable solvent a solution of cadmium, or a compound thereof, in a form suitable for the generation of a nanocrystal. The solvent includes a compound selected from an ether and an amine. In some embodiments the solvent includes an alkene. Furthermore the solvent is at least essentially free of tri-n-octylphosphine oxide. The method includes bringing the solution to a temperature selected in the range from about 20° C. to about 200° C. The method also includes adding at the temperature selected in the range from about 20° C. to about 200° C. the element A in a form suitable for the generation of a nanocrystal. Thereby the forming of a nanocrystal of the composition CdA is allowed.
According to some particular embodiments, forming a solution of a cadmium compound is carried out by forming a cadmium organic salt by reacting its oxide or inorganic salts with a long chain organic acid.
In a related aspect the present invention provides a method of forming a nanocrystal of the composition CdA, with A being S or Se. The method includes forming in a suitable solvent a solution of a cadmium organic salt by reacting, for example, its oxide or an inorganic salt with a long chain organic acid, or a compound thereof, in a form suitable for the generation of a nanocrystal. The solvent is selected from the group consisting of dioctyl ether, 1-octadecene, oleylamine and any combination thereof. The method further includes bringing the solution to a temperature selected in the range from about 20° C. to about 200° C. The method also includes adding at the temperature selected in the range from about 20° C. to about 200° C. the element A in a form suitable for the generation of a nanocrystal. Thereby the forming of a nanocrystal of the composition CdA is allowed.
The nanocrystal obtained by a method of the invention is typically homogenous.
In a further aspect the invention also relates to the use of a nanocrystal obtained by one of the above methods in the manufacture of an illuminant.
The invention will be better understood with reference to the detailed description when considered in conjunction with the accompanying drawings, in which:
As can be taken from these appended figures, high quality nanocrystals can be formed using the method of the present invention at mild reaction conditions. Fully controlled paramaters allow for the fine adjustment of desired properties of the obtained nanocrystals. As an example, a nanocrystal obtained by the method of the present invention may be used in an illuminant, an amplifier, in a biological sensor or for computation methods. When used in an illuminant, i.e. a light emitting device such as a lamp, a light emitting diode, a laser diode, a fluorophore (for instance in the detection of tumors), a TV-screen or a computer monitor, the wavelength range, including the peak of light emission, can be adjusted by selecting values for process parameters in the method of the invention. One such embodiment of the invention is a nanocrystal that emits white light. Accordingly, the present invention also relates to the use of a nanocrystal obtainable or obtained by the method of the invention. As can be taken by the illustrative figures, the respective wavelength range, including the emission peak, can be controlled by factors such as the temperature at which the element A is added, the reaction time, the solvent used, the surfactant used, and the amount of surfactant added.
Any suitable solvent may be used in the method of the present invention as long as its main component is not tri-n-octylphosphine oxide (see also below). Typically the solvent is or includes a coordinating solvent. The solvent includes an ether or an amine, such as an alkylamine or a dialkylamine. In typical embodiments the solvent is a weak coordinating solvent. It may also include non-coordinating components such as an alkane or an alkene (see below) or strong coordinating components such as tri-n-octylphosphine.
The solvent used in the method of the invention is typically a high-boiling solvent, e.g. with a boiling point above about 120° C., 150° C., 180° C. or above about 220° C. In some embodiments a combination of solvent components is selected, which has a boiling point above the highest selected temperature during the method of the invention (e.g. for dissolving cadmium or a cadmium compound). The ether or amine itself may be a high-boiling solvent. Examples of a suitable ether include, but are not limited to, dioctylether (CAS-No. 629-82-3), didecyl ether (CAS-No. 2456-28-2), diundecyl ether (CAS-No. 43146-97-0), didodecyl ether (CAS-No. 4542-57-8), 1-butoxy-dodecane (CAS-No. 7289-38-5), heptyl octyl ether (CAS-No. 32357-84-9), octyl dodecyl ether (CAS-No. 36339-51-2), and 1-propoxy-heptadecane (CAS-No. 281211-90-3). Examples of a suitable amine include, but are not limited to, 1-amino-9-octadecene (oleylamine) (CAS-No. 112-90-3), 1-amino-4-nonadecene (CAS-No. 25728-99-8), 1-amino-7-hexadecene (CAS-No. 225943-46-4), 1-amino-8-heptadecene (CAS-No. 712258-69-0, CAS-No of the pure Z-isomer: 141903-93-7), 1-amino-9-heptadecene (CAS-No. 159278-11-2, CAS-No of the Z-isomer: 906450-90-6), 1-amino-9-hexadecene (CAS-No. 40853-88-1), 1-amino-9-eicosene (CAS-No. 133805-08-0), 1-amino-9,12-octadecadiene (CAS-No. 13330-00-2), 1-amino-8,11-heptadecadiene (CAS-No. 141903-90-4), 1-amino-13-docosene (CAS-No. 26398-95-8), N-9-octadecenyl-propanediamine (CAS-No. 29533-51-5), N-10. octyl-2,7-octadienyl-amine (CAS-No. 67363-03-5), N-9-octadecen-1-yl-9-octadecen-1-amine (dioleylamine) (CAS-No. 40165-68-2), bis(2,7-octadienyl)amine (CAS-No. 31334-50-6), and N,N-Dibutyl-2,7-octadienylamine (CAS-No. 63407-62-5).
Other compounds that may be included in the solvent include, but are not limited to, an alkyl- or aryl phosphine, a phospine oxide, an alkane, or an alkene. The respective compounds may include long chain alkyl or aryl groups, such as dodecylamine, hexadecylamine, octa-decylamine, etc. It is however noted that compounds with such long chain moieties are not required in the method of the present invention. Illustrative examples of an alkene include, but are not limited to, 1-dodecene (CAS-No 112-41-4), 1-tetradecene (CAS-No 1120-36-1), 1-hexadecene (CAS No. 629-73-2), 1-heptadecene (CAS No. 6765-39-5), 1-octadecene (CAS No. 112-88-9), 1-eicosene (CAS No. 3452-07-1), 7-tetradecene (CAS-No 1037474-0), 9-hexacosene (CAS-No 71502-22-2), 1,13-tetradecadiene (CAS No21964-49-8) or 1,17-octa-decadiene (13560-93-5). Illustrative examples of an alkane are decane (CAS-No 124-18-5), undecane (CAS-No 1120-21-4), tridecane (CAS-No 629-50-5), hexadecane (CAS-No 544-76-3), octadecane (CAS-No 593-45-3), dodecane (CAS-No 112-40-3) and tetradecane (CAS-No 629-59-4). Illustrative examples of a phosphine are trioctylphosphine, tributylphosphine, tri (dodecyl) phosphine. Illustrative examples of a phosphine oxide are trioctylphosphine oxide, tris(2-ethylhexyl) phosphine oxide, and phenylbis(2,4,6-trimethylbenzoyl)-phosphine oxide. Noteworthy, the method of the present invention can however be performed in the absence of alkanes, alkenes, phosphines or phosphine oxides. Such solvents, which are continuously being used in approaches to improve the performance of the method of Bowers et al. (see above, cf. e.g. Jose, R., et al., Applied Physics Letters [2006] 89, 013115) or Japanese patent application JP 2006-143526, are generally cost intensive and thus provide an obstacle to upscaling and economic production.
In some embodiments of the method of the invention the solvent includes both an alkene and an amine. The alkene and the amine may be present in any ratio, such as for instance in the range of about 100:1 (v/v) to about 1:100 (v/v), 10:1 (v/v) to about 1:10 (v/v) or about 5:1 (v/v) about 1:5 (v/v). In some embodiments the solvent includes both an alkyl phosphine or an aryl phosphine and an amine. The phosphine and the amine may also be present in any ratio, such as for instance in the range of about 100:1 (v/v) to about 1:100 (v/v), 10:1 (v/v) to about 1:10 (v/v) or about 5:1 (v/v) about 1:5 (v/v).
The solvent is at least essentially free of tri-n-octylphosphine oxide. The term “at least essentially free of” as used herein for a solvent refers to the use of amounts of a solvent that do not significantly affect the total fluid content. This term thus includes the complete absence and the presence of traces of the solvent, for example about 0,01%, about 0,1%, about 0.5%, about 1%, about 2%, about 3%, about 4% or about 5% (in relation to the total volume of the used solvent). Accordingly the main solvent (which can also be a mixture of different solvents other than tri-n-octylphosphine oxide) in the method of the present invention, in which a solution of cadmium, or a compound thereof, is prepared, is, or is dominated and governed, by a solvent that differs from tri-n-octylphosphine oxide.
In the respective solvent (or mixture of solvents) a solution of a cadmium compound is formed. Any cadmium compound may be used that can be dissolved in the selected solvent. The cadmium compound may for example be elemental cadmium, an organic cadmium salt or an inorganic cadmium salt such as cadmium carbonate or cadmium chloride). The compound may also be cadmium oxide which by dissolving the same will be converted into a cadmium salt such as an inorganic or organic salt. Forming a solution of the cadmium compound, respectively, may in some embodiments include bringing the solvent to an elevated temperature. After dissolving cadmium or the cadmium compound, the temperature of the solution may be changed, such as reduced to a selected temperature.
In some embodiments a solution of a cadmium organic compound is formed in the solvent. The cadmium organic compound may be dispersed, typically directly, in the solvent. The cadmium organic compound may also be obtained by or having its inorganic counterparts reacting with a long chain organic acid, possibly, in the presence of the solvent. Most of inorganic cadmium compounds may be used to form soluble organic salts in the selected solvent. Examples of a suitable starting cadmium compound include, but are not limited to, cadmium oxide, cadmium carbonate (CdCO3), cadmium nitrate (Cd(NO3)2), cadmium chloride (CdCl2), dimethylcadmium (CdMe2), cadmium acetate (Cd(Ac)2), cadmium oleate (Cd(OA)2) and cadmium stearate, to mentioned only a few.
The method of the invention may also include adding a surfactant. The surfactant may be added to the solvent before a solution of cadmium, or a cadmium compound, is formed, or at the same time. The surfactant may also be added to the solution of cadmium, or the cadmium compound, which has been formed in the respective solvent. Typically the surfactant is added before sulphur or selenium (see also below), or a compound thereof, are added. Any surfactant may be used. The surfactant may for instance be an organic carbonic acid (carboxylic acid), an organic phosphate, an organic phosphonic acid or a mixture thereof. Illustrative examples of suitable organic carbonic acid include, but are not limited to, stearic acid (octadecanoic acid), lauric, acid, oleic acid ([Z]-octadec-9-enoic acid), n-undecanoic acid, linoleic acid, ((Z,Z)-9,12-octadecadienoic acid), arachidonic acid ((all-Z)-5,8,11,14-eicosa-tetraenoic acid), linelaidic acid ((E,E)-9,12-octadecadienoic acid), myristoleic acid (9-tetrade-cenoic acid), palmitoleic acid (cis-9-hexadecenoic acid), myristic acid (tetradecanoic acid), palmitic acid (hexadecanoic acid) and γ-homolinolenic acid ((Z,Z,Z)-8,11,14-eicosatrienoic acid). Examples of other surfactants (an organic phosphonic acid, for example) include hexyl-phosphonic acid and tetra decylphosphonic acid. It has previously been observed that oleic acid is capable of stabilising nanocrystals and allows the usage of octadecene as a solvent (Yu, W. W., & Peng, X., Angew. Chem. Int. Ed. (2002) 41, 13, 2368-2371). In the synthesis of other nanocrystals surfactants have been shown to affect the crystal morphology of the nano crystals formed (Zhou, G, et al., Materials Lett. (2005) 59, 2706-2709). The present inventors made the surprising finding that the usage of a surfactant in combination with a suitable solvent allows mild reaction conditions (even in the absence of an inert gas atmosphere) at a high concentration (see also below).
In some embodiments a solution of an inorganic cadmium salt is formed. Upon adding an organic acid such as an organic carbonic acid (see above for examples), which is typically a long chain organic carbonic acid, to the solution of the inorganic cadmium salt (which can also be obtained by dissolving cadmium oxide, see above) an organic cadmium salt such as cadmium salt of an organic carbonic acid, may be formed. It is noted in this regard the formation of a complex mixture has been observed in the case of indium compounds (Lucey, D. W., et al., Chem. Mater. (2005) 17, 3754-3762).
In the method of the invention the solution of cadmium or the cadmium compound is brought to a temperature selected in the range from about 20° C. to about 200° C., such as about 30° C. to about 180° C., about 40° C. to about 160° C. or about 70° C. to about 160° C. The temperature may for instance be about 60° C., about 80° C., about 100° C., about 120° C. or about 160° C. At the respective temperature the element A, i.e. sulphur or selenium, is added in a form suitable for the generation of a nanocrystal. The respective element may be added in any suitable solvent such as for instance a phosphine, e.g. tri-n-octylphosphine (CAS No. 4731-53-7), tri-n-nonyl-phosphine (CAS No. 17621-06-6), tri-n-heptylphosphine (CAS No 17621-04-4), tri-n-hexylphosphine (CAS No. 4168-73-4), tri-n-butylphosphine (CAS No 998-40-3), tri-p-tolyl-phosphine (CAS No 1038-95-5), tri-1-naphthyl-phosphine (CAS No 3411-48-1) or triphenylphosphine (CAS No 603-35-0).
The reaction may be carried out for any desired period of time, ranging from milliseconds to a plurality of hours. Where desired, the reaction is carried out in an inert atmosphere, i.e. in the presence of gases that are not reactive, or at least not reactive to a detectable extent, with regard to the reagents and solvents used Examples of a reactive inert atmosphere are nitrogen or a noble gas such as argon or helium. It is however noteworthy that an inert gas atmosphere was found to be generally unnecessary.
The method of the invention can conveniently be used to prepare nanocrystals, including white light emitting quantum dots, at mild reaction conditions. Compared to known methods of forming quantum dots the present method allows the preparation of (colour) quantum dots at a high concentration. Compared to the method disclosed by Bowers et al. (2005, supra), for example, the present method has for instance been found to result in the formation of a preparation of quantum dots with a 5˜10 times higher concentration.
The method of the present invention is furthermore particularly suitable for forming conventional quantum dots with relatively narrow emission peaks (fwhm˜23 nm). Under the mild reaction conditions it is plain sailing to tune the wavelength of the emission peak in fine increment (Δλ=1 nm). By selecting a particular reaction temperature and a particular reaction time (see e.g.
The method of the invention may further include nanocrystal post-processing. Although the nanocrystals obtained by the method of the invention are generally at least essentially or at least almost monodisperse, if desired a step may be performed to narrow the size-distribution (for example as a precaution or a safety-measure). Such techniques, e.g. size-selective precipitation, are well known to those skilled in the art. The surface of the nanocrystal may also be altered, for instance coated.
In some embodiments the nanocrystal (or the plurality thereof) formed by the method of the invention is coupled to a molecule with binding affinity for a selected target molecule, such as a microorganism, a virus particle, a peptide, a peptoid, a protein, a nucleic acid, a peptide, an oligosaccharide, a polysaccharide, an inorganic molecule, a synthetic polymer, a small organic molecule or a drug.
The term “nucleic acid molecule” as used herein refers to any nucleic acid in any possible configuration, such as single stranded, double stranded or a combination thereof. Nucleic acids include for instance DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogues of the DNA or RNA generated using nucleotide analogues or using nucleic acid chemistry, locked nucleic acid molecules (LNA), and protein nucleic acids molecules (PNA). DNA or RNA may be of genomic or synthetic origin and may be single or double stranded. In the present method of the invention typically, but not necessarily, an RNA or a DNA molecule will be used. Such nucleic acid can be e.g. mRNA, cRNA, synthetic RNA, genomic DNA, cDNA synthetic DNA, a copolymer of DNA and RNA, oligonucleotides, etc. A respective nucleic acid may furthermore contain non-natural nucleotide analogues and/or be linked to an affinity tag or a label. In some embodiments the nucleic acid molecule may be isolated, enriched, or purified. The nucleic acid molecule may for instance be isolated from a natural source by cDNA cloning or by subtractive hybridization. The natural source may be mammalian, such as human, blood, semen, or tissue. The nucleic acid may also be synthesized, e.g. by the triester method or by using an automated DNA synthesizer.
Many nucleotide analogues are known and can be used in nucleic acids and oligonucleotides used in the methods of the invention. A nucleotide analogue is a nucleotide containing a modification at for instance the base, sugar, or phosphate moieties. Modifications at the base moiety include natural and synthetic modifications of A, C, Q and T/U, different purine or pyrimidine bases, such as uracil-5-yl, hypoxanthin-9-yl, and 2-aminoadenin-9-yl, as well as non-purine or non-pyrimidine nucleotide bases. Other nucleotide analogues serve as universal bases. Universal bases include 3-nitropyrrole and 5-nitroindole. Universal bases are able to form a base pair with any other base. Base modifications often can be combined with for example a sugar modification, such as for instance 2′-O-methoxyethyl, e.g. to achieve unique properties such as increased duplex stability.
A peptide may be of synthetic origin or isolated from a natural source by methods well-known in the art. The natural source may be mammalian, such as human, blood, semen, or tissue. A peptide, including a polypeptide may for instance be synthesized using an automated polypeptide synthesizer. Illustrative examples of polypeptides are an antibody, a fragment thereof and a proteinaceous binding molecule with antibody-like functions. Examples of (recombinant) antibody fragments are Fab fragments, Fv fragments, single-chain Fv fragments (scFv), diabodies, triabodies (Iliades, P., et al., FEBS Lett (1997) 409, 437-441), decabodies (Stone, E., et al., Journal of Immunological Methods (2007) 318, 88-94) and other domain antibodies (Holt, L. J., et al., Trends Biotechnol. (2003), 21, 11, 484-490). An example of a proteinaceous binding molecule with antibody-like functions is a mutein based on a polypeptide of the lipocalin family (WO 03/029462, Beste et al., Proc. Natl. Acad. Sci. U.S.A. (1999) 96, 1898-1903). Lipocnlins, such as the bilin binding protein, the human neutrophil gelatinase-associated lipocalin, human Apolipoprotein D or glycodelin, posses natural ligand-binding sites that can be modified so that they bind to selected small protein regions known as haptens. Examples of other proteinaceous binding molecules are the so-called glubodies (see e.g. internation patent application WO 96/23879), proteins based on the ankyrin scaffold (Mosavi, L. K., et al., Protein Science (2004) 13, 6, 1435-1448) or crystalline scaffold (e.g. internation patent application WO 01/04144) the proteins described in Skerra, J. Mol. Recognit. (2000) 13, 167-187, AdNectins, tetranectins and avimers. Avimers contain so called A-domains that occur as strings of multiple domains in several cell surface receptors (Silverman, J., et al., Nature Biotechnology (2005) 23, 1556-1561). Adnectins, derived from a domain of human fibronectin, contain three loops that can be engineered for immunoglobulin-like binding to targets (Gill, D. S. & Damle, N. K., Current Opinion in Biotechnology (2006) 17, 653-658). Tetranectins, derived from the respective human homotrimeric protein, likewise contain loop regions in a C-type lectin domain that can be engineered for desired binding (ibid.). Peptoids, which can act as protein ligands, are oligo(N-alkyl) glycines that differ from peptides in that the side chain is connected to the amide nitrogen rather than the α carbon atom. Peptoids are typically resistant to proteases and other modifying enzymes and can have a much higher cell permeability than peptides (see e.g. Kwon, Y.-U., and Kodadek, T., J. Am. Chem. Soc. (2007) 129, 1508-1509).
As a further illustrative example, a linking moiety such as an affinity tag may be used to immobilise the respective molecule. Such a linking moiety may be a molecule, e.g. a hydrocarbon-based (including polymeric) molecule that includes nitrogen-, phosphorus-, sulphur-, carben-, halogen- or pseudohalogen groups, or a portion thereof. As an illustrative example, the selected surface may include, for instance be coated with, a brush-like polymer, for example with short side chains. The immobilisation surface may also include a polymer that includes a brush-like structure, for example by way of grafting. It may for example include functional groups that allow for the covalent attachment of a biomolecule, for example a molecule such as a protein, a nucleic acid molecule, a polysaccharide or any combination thereof. Examples of a respective linking moietyfunctional group include, but are not limited to, an amino group, an aldehyde group, a thiol group, a carboxy group, an ester, an anhydride, a sulphonate, a sulphonate ester, an imido ester, a silyl halide, an epoxide, an aziridine, a phosphoramidite and a diazoalkane.
Examples of an affinity tag include, but are not limited to biotin, dinitrophenol or digoxigenin, oligohistidine, polyhistidine, an immunoglobulin domain, maltose-binding protein, glutathione-5-transferase (GST), calmodulin binding peptide (CBP), FLAG′-peptide, the T7 epitope (Ala-Ser-Met-Thr-Gly-Gly-Gln-Gln-Met-Gly), maltose binding protein (MBP), the HSV epitope of the sequence Gln-Pro-Glu-Leu-Ala-Pro-Glu-Asp-Pro-Glu-Asp of herpes simplex virus glycoprotein D, the hemagglutinin (HA) epitope of the sequence Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala, the “myc” epitope of the transcription factor c-myc of the sequence Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu, or an oligonucleotide tag. Such an oligonucleotide tag may for instance be used to hybridise to an immobilised oligonucleotide with a complementary sequence. A further example of a linking moiety is an antibody, a fragment thereof or a proteinaceous binding molecule with antibody-like functions (see also above).
A further example of linking moiety is a cucurbituril or a moiety capable of forming a complex with a cucurbituril. A cucurbituril is a macrocyclic compound that includes glycoluril units, typically self-assembled from an acid catalyzed condensation reaction of glycoluril and formaldehyde. A cucurbit[n]uril, (CB[n]), that includes n glycoluril units, typically has two portals with polar ureido carbonyl groups. Via these ureido carbonyl groups cucurbiturils can bind ions and molecules of interest. As an illustrative example cucurbit[7]uril (CB[7]) can form a strong complex with ferrocenemethylammonium or adamantylammonium ions. Either the cucurbit[7]uril or e.g. ferrocenemethylammonium may be attached to a biomolecule, while the remaining binding partner (e.g. ferrocenemethylammonium or cucurbit[7]uril respectively) can be bound to a selected surface. Contacting the biomolecule with the surface will then lead to an immobilisation of the biomolecule. Functionalised CB[7] units bound to a gold surface via alkanethiolates have for instance been shown to cause an immobilisation of a protein carrying a ferrocenemethylammonium unit (Hwang, I., et al., J. Am. Chem. Soc. (2007) 129, 4170-4171).
Further examples of a linking moiety include, but are not limited to an oligosaccharide, an oligopeptide, biotin, dinitrophenol, digoxigenin and a metal chelator (cf. also below). As an illustrative example, a respective metal chelator, such as ethylenediamine, ethylenediaminetetraacetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA), diethylene-triaminepentaacetic acid (DTPA), N,N-bis(carboxymethyl)glycine (also called nitrilotriacetic acid, NTA), 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA), 2,3-dimer-capto-1-propanol (dimercaprol), porphine or heme may be used in cases where the target molecule is a metal ion. As an example, EDTA forms a complex with most monovalent, divalent, trivalent and tetravalent metal ions, such as e.g. silver (Ag+), calcium (Ca2+), manganese (Mn2+), copper (Cu2+), iron (Fe2+), cobalt (Co3+) and zirconium (Zr4+), while BAPTA is specific for Ca2+. In some embodiments a respective metal chelator in a complex with a respective metal ion or metal ions defines the linking moiety. Such a complex is for example a receptor molecule for a peptide of a defined sequence, which may also be included in a protein. As an illustrative example, a standard method used in the art is the formation of a complex between an oligohistidine tag and copper (Cu2+), nickel (Ni2+), cobalt (Co2+), or zink (Zn2+) ions, which are presented by means of the chelator nitrilotriacetic acid (NTA).
Avidin or streptavidin may for instance be employed to immobilise a biotinylated nucleic acid, or a biotin containing monolayer of gold may be employed (Shumaker-Parry, J. S., et al., Anal. Chem. (2004) 76, 918). As yet another illustrative example, the biomolecule may be locally deposited, e.g. by scanning electrochemical microscopy, for instance via pyrrole-oligonucleotide patterns (e.g. Fortin, E., et al., Electroanalysis (2005) 17, 495). In other embodiments, in particular where the biomolecule is a nucleic acid, the biomolecule may be directly synthesised on the surface of the immobilisation unit, for example using photoactivation and deactivation. As an illustrative example, the synthesis of nucleic acids or oligonucleotides on selected surface areas (so called “solid phase” synthesis) may be carried out using electrochemical reactions using electrodes. An electrochemical deblocking step as described by Egeland & Southern (Nucleic Acids Research (2005) 33, 14, e125) may for instance be employed for this purpose. A suitable electrochemical synthesis has also been disclosed in US patent application US 2006/0275927. In some embodiments light-directed synthesis of a biomolecule, in particular of a nucleic acid molecule, including UV-linking or light dependent 5′-deprotection, may be carried out.
The molecule that has a binding affinity for a selected target molecule may be immobilised on the nanocrystals by any means. As an illustrative example, an oligo- or polypeptide, including a respective moiety, may be covalently linked to the surface of nanocrystals via a thio-ether-bond, for example by using ω functionalized thiols. Any suitable molecule that is capable of linking a nanocrystal of the invention to a molecule having a selected binding affinity may be used to immobilise the same on a nanocrystal. For instance a (bifunctional) linking agent such as ethyl-3-dimethylaminocarbodiimide, N-(3-aminopropyl) 3-mercapto-benzamide, 3-aminopropyl-trimethoxysilane, 3-mercaptopropyl-trimethoxysilane, 3-(trimethoxysilyl) propyl-maleimide, or 3-(trimethoxysilyl) propyl-hydrazide may be used. Prior to reaction with the linking agent, the surface of the nanocrystals can be modified, for example by treatment with glacial mercaptoacetic acid, in order to generate free mercaptoacetic groups which can then employed for covalently coupling with an analyte binding partner via linking agents.
Exemplary embodiments of methods according to the invention as well as reactants and further processes that may be used are shown in the appending figures.
A colloidal wet chemistry approach was universally taken in the following examples. Dioctyl ether (99%), tri-n-octyl phosphine (TOP, 90%), 1-octadecene (ODE, 90%), oleylamine (70%), oleic acid (90%), and selenium (100 mesh, 99.999%) were all products of Sigma-Aldrich Chemie GmbH, Germany; Cadmium oxide (99.999%) was a product of Strem Chemicals, USA.
Mostly quantum dots with narrow emission peaks were prepared in a non-water solvent with high boiling point (TOPO, TOP, ODE, dioctyl ether, oleylamine, or a mixture solvent from two or more of these solvents). The capping agents used to passivate the highly energetic surface of the quantum dots were TOPO, oleic acid, etc. The as-prepared quantum dots can be dispersed in non-water solvents, such as hexane, chloroform, and toluene. Their water-soluble counterparts may be obtained via a surface ligand exchange process, and the complexity depends on the stability of the quantum dots.
The methods of the following examples use an exemplary selected solvent or solvent combination, do not require long chain alkylamine compounds as starting material and are performed at low reaction temperatures. The crude products were in all cases found to be of a 5˜10 times higher concentration than previously achieved. The examples include detailed comparisons, which include the quantum dots preparation at different reaction temperatures, in different solvents, as well as with different ratio of cadmium oxide to the oleic acid applied. Further, polymer/quantum dots hybrid materials fabrications from these quantum dots are presented.
0.128 g cadmium oxide (CdO, 1.0 mmol) was put together with 1.28 ml of oleic acid (4.0 mmol) and 12 mL of dioctyl ether in a 50 mL reaction flask, equipped with thermometer sensor. After degassing the reaction mixture was heated to 250° C. (all temperature numbers in this document refer to centigrade). As soon as a clear and colorless solution formed, the solution was cooled down to 120° C., 1.2 ml of 1M selenium/TOP solution, prepared by dissolving 3.95 g of 100 mesh selenium in 50 mL of TOP, was injected into the reaction flask. After 2 minutes of reaction, the heater was removed and the reaction mixture was poured into cold n-hexane immediately. Mixing methanol with same volume of the n-hexane solution obtained, a phase separation will occur. Discarding the bottom layer (consisting of n-hexane, methanol, dioctyl ether, TOP, as well as some unreacted oleic acid). Washing the mixture once more with n-hexane/methanol mixture (v/v, 1:1), the white quantum dots can be precipitated with methanol (if the volume of n-hexane is big, phase separation may appear again, and the volume of the top layer will be largely reduced. Discarding the bottom layer and continue with methanol for the precipitation process) or acetone (using acetone may lose part of the product due to the noticeable solubility of the quantum dots in the mixture of n-hexane and acetone), and collected by centrifugation. The obtained pellet can be dispersed in n-hexane, toluene or chloroform for further application or characterization.
The quantum dots emitting such a white light may possess a narrow size distribution, but possibly also a distribution profile with several peaks (centers on different sizes) which resembles the case of mixing several narrow dispersed quantum dots together (according to the common understandings). A way to test this out is to let the prepared white quantum dots further grow at 120° C., and take aliquots at different reaction intervals and quench them with cold n-hexane. The experiments were conducted and the photoluminescence spectra were recorded from the aliquots samples. In
Two more examples are given to show the preparation of such CdSe quantum dots at different temperature. The first one was to conduct the reaction at 80° C., i.e., injecting the 1.2 mL of TOP/Se solution into the reaction flask at 80° C. after the formation of a clear solution from the mixture of cadmium oxide (0.128 g, 1.0 mmol), oleic acid (1.28 mL, 4.0 mmol) and dioctyl ether (12 mL). Again aliquots of the reaction mixture were taken at certain intervals and injected into cold n-hexane.
In
As can be taken from
A further observation is that the red-shift of the PL peak (growth of quantum dots) in all cases takes place faster at the beginning, and the shift rate decreases gradually with the reaction time. The reason is that with time the concentration of monomers used for the growth of quantum dots is reduced. Further, even if the reaction rate is constant (i.e., produces same volume, ΔV, of products in a certain reaction period, ignoring the deficiency of the reactant materials), the rate of increase of the particle diameter (ΔD) decreases when the particles grow larger
Since the increase in diameter roughly correlates with the increase in emission wavelength, a smaller change in the rate of increase of the emission wavelength with time is reasonable. Furthermore
For reactions at lower temperatures, however, the Nucleation→Focusing→Oswald Ripening process is not as prominent. A respective example is shown in
Besides dioctyl ether, TOP, 1-octadecene (ODE), oleylamine, TOP/oleylamine, and ODE/oleylamine have also been used as solvent for the preparation of CdA quantum dots, respectively. All are liquid at room temperature with ODE being the most commercially favorable choice (18.56 S$/liter for 100 L).
With ti-n-octylphosphine (TOP) as the solvent, a slight modification was applied in the preparation. Instead of adding the solvent at the starting point of the reaction, cadmium oleate was first prepared by reacting cadmium oxide with oleic acid alone, before the addition of the reaction solvent. The protocol of the reaction is as follows:
0:128 g cadmium oxide (1.0 mmol) was mixed with 1.28 ml oleic acid (4.0 mmol) in a 50 mL 3-neck reaction flask equipped with a thermometer sensor. After degassing the mixture was heated to 250° C. while stirring, until the dark-brown solid was completely dissolved and a lightly colored clear solution formed. Injecting 12 ml of TOP into the reaction flask and set the temperature to 120° C. At 120° C., 1.2 ml 1M TOP/Se solution was injected. Aliquots were then taken from the reaction mixtures at different reaction intervals and quenched with cold toluene.
If ODE/oleylamine or oleylamine alone is used as reaction solvent, the reaction rate at the initial state is much slower. Even after 2 minutes of reaction the quantum dots generated still possess a wide emission peak centered at 360-390 nm. White quantum dots, in this case, could be obtained by quenching the reaction mixture between 2 and 5 minutes. Depending on the time-point of the quenching, one may get cool-white, white or warm white emission light.
Noteworthy, when ODE/oleylamine (v/v: 1:1) or oleylamine were used as the solvent, a phase separation occurred after the product was stored for a while. The quantum dots stayed at the bottom layer with a concentration 5˜10 times higher than the original concentration. In contrast thereto, most of the solvents and unreacted substances remained in the upper layer. This, on one hand, very much simplified the purification; on the other hand, the upper layer can be further used for the preparation of the next batches of the same product. Both will lead to a lower production cost
A change in the ratio between cadmium oxide and oleic acid also affects the parameters of quantum dots. The stoichiometric ratio between CdO and oleic acid is 1:2 for the preparation of cadmium oleate, one of the key components for the formation of CdSe quantum dots. Considering the purity grade (90%) of oleic acid, this minimum ratio would be 1:2.3. In order to get monodispersed quantum dots, some free ligands (oleic acid in this case) should exist when the reaction starts. A few tests indicated that for including the oleic acid at the beginning of reaction, the minimum amount of oleic acid should be 3 times of that of cadmium oxide. An increase of the oleic acid which corresponds to a higher ligand concentration, results in the quantum dots obtained at the same reaction period getting smaller. If the ratio between oleic acid and cadmium oxide is larger than 7, the quantum yield drops dramatically. At a ratio of 3˜4, high quality quantum dots can be prepared.
The as-prepared (crude) quantum dots were first washed with the protocol below, which is a modification of the procedure used in the art:
1 ml of crude CdSe quantum dots was dispersed in 4 ml of toluene in a 15-ml centrifugation tube. 8 ml of methanol was then added into the tube. After vortexing and centrifugation, oil-like residue appeared at the bottom of the tube. The residue was dispersed in 4 ml toluene again and followed by another 8 ml of methanol. Solid materials were obtained after another vortexing and centrifugation. The solid was dispersed in a prepared polymer (conventional polystyrene or photoconductive polyvinylcarbazole) toluene solution with desired concentrations. The obtained solution was vortexed to enable a sufficient mixing of the quantum dots with polymer chains. Thin films were then fabricated from the solution by casting or spin-coating onto different substrates (metal coated optical glass slides, fused silica slides, quartz crystal sensors, silicon wafers, and etc.) for different application purposes.
The listing or discussion of a previously published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge. All documents listed are hereby incorporated herein by reference in their entirety for all purposes as if each individual document were specifically and individually indicated to be incorporated by reference.
The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising”, “including,” containing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognised that various modifications are possible within the scope of the invention claimed. Additional objects, advantages, and features of this invention will become apparent to those skilled in the art upon examination of the foregoing examples and the appended claims. Thus, it should be understood that although the present invention is specifically disclosed by exemplary embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognise that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/SG07/00235 | 8/6/2007 | WO | 00 | 10/28/2011 |